 |
市場調査レポート
商品コード
1412448
婦人科がん治療薬市場：適応症別、薬剤クラス別、流通チャネル別、エンドユーザー別-2024～2030年の世界予測Gynecological Cancer Drugs Market by Indication (Cervical Cancer, Chemotherapy, Ovarian & Fallopian Tube Cancer), Drug Class (Alkylating Agent, Anthracyclines, Antitumor Antibiotic), Distribution Channel, End-users - Global Forecast 2024-2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| 婦人科がん治療薬市場：適応症別、薬剤クラス別、流通チャネル別、エンドユーザー別-2024～2030年の世界予測 |
|
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
|
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
- 全表示
- 概要
- 図表
- 目次
概要
婦人科がん治療薬市場規模は2023年に93億6,000万米ドルと推計され、2024年には103億5,000万米ドルに達し、CAGR 11.95%で2030年には206億5,000万米ドルに達すると予測されます。
婦人科がん治療薬の世界市場
| 主な市場の統計 | |
|---|---|
| 基準年[2023］ | 93億6,000万米ドル |
| 予測年[2024］ | 103億5,000万米ドル |
| 予測年 [2030] | 206億5,000万米ドル |
| CAGR（%） | 11.95% |
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは婦人科がん治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。
市場シェア分析
市場シェア分析は、婦人科がん治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。
本レポートは、以下の側面に関する貴重な洞察を提供しています：
1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。
2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。
3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。
5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。
本レポートは、以下のような主要な質問に対応しています：
1-婦人科がん治療薬市場の市場規模および予測は？
2-婦人科がん治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？
3-婦人科がん治療薬市場における技術動向と規制の枠組みは？
4-婦人科がん治療薬市場における主要ベンダーの市場シェアは？
5-婦人科がん治療薬市場への参入に適した形態や戦略的手段は？
目次
第1章 序文
第2章 調査手法
第3章 エグゼクティブサマリー
第4章 市場の概要
第5章 市場洞察
- 市場力学
- 促進要因
- さまざまな婦人科がんの罹患率の上昇
- 女性の高齢化とヘルスケア意識の高まり
- 治療薬と予防薬の両方を開発する政府の取り組み
- 抑制要因
- 婦人科がん治療薬の作成に伴う高コストと品質の問題
- 機会
- 新たな卵巣がん治療法の開発とイントロダクション
- 近代化されたヘルスケアインフラと新薬への投資の増加
- 課題
- 医薬品の承認に関連する厳格な規制の枠組み
- 促進要因
- 市場セグメンテーション分析
- 市場動向分析
- 高インフレの累積的影響
- ポーターのファイブフォース分析
- バリューチェーンとクリティカルパス分析
- 規制の枠組み
第6章 婦人科がん治療薬市場適応症別
- 子宮頸がん
- 化学療法
- 卵巣がんおよび卵管がん
- 子宮がん
- 膣がん
- 外陰がん
第7章 婦人科がん治療薬市場薬剤クラス別
- アルキル化剤
- アントラサイクリン系
- 抗腫瘍抗生物質
- 植物アルカロイド
第8章 婦人科がん治療薬市場：流通チャネル別
- eコマース
- 病院薬局
- 小売薬局
第9章 婦人科がん治療薬市場：エンドユーザー別
- クリニック
- 病院
- がん専門治療センター
第10章 南北アメリカの婦人科がん治療薬市場
- アルゼンチン
- ブラジル
- カナダ
- メキシコ
- 米国
第11章 アジア太平洋地域の婦人科がん治療薬市場
- オーストラリア
- 中国
- インド
- インドネシア
- 日本
- マレーシア
- フィリピン
- シンガポール
- 韓国
- 台湾
- タイ
- ベトナム
第12章 欧州・中東・アフリカの婦人科がん治療薬市場
- デンマーク
- エジプト
- フィンランド
- フランス
- ドイツ
- イスラエル
- イタリア
- オランダ
- ナイジェリア
- ノルウェー
- ポーランド
- カタール
- ロシア
- サウジアラビア
- 南アフリカ
- スペイン
- スウェーデン
- スイス
- トルコ
- アラブ首長国連邦
- 英国
第13章 競合情勢
- FPNVポジショニングマトリクス
- 市場シェア分析：主要企業別
- 競合シナリオ主要企業別の分析
第14章 競争力のあるポートフォリオ
- 主要な企業プロファイル
- Abbott Laboratories
- AbbVie Inc.
- Alnylam Pharmaceuticals, Inc.
- Amgen Inc.
- Apotex Pharmaceutical Holdings Inc.
- AstraZeneca PLC
- Bayer AG
- Biocon Limited
- Bristol-Myers Squibb Company
- Clovis Oncology
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Genentech Inc.
- GlaxoSmithKline PLC
- ImmunoGen, Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- TherapeuticsMD Inc.
- VBL Therapeutics, Inc.
- 主要な製品ポートフォリオ
第15章 付録
- ディスカッションガイド
- ライセンスと価格について
図表
LIST OF FIGURES
- FIGURE 1. GYNECOLOGICAL CANCER DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GYNECOLOGICAL CANCER DRUGS MARKET DYNAMICS
- FIGURE 7. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 8. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 10. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 12. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
- FIGURE 14. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
LIST OF TABLES
- TABLE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 6. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
- TABLE 7. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 8. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN & FALLOPIAN TUBE CANCER, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VAGINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 13. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLANT ALKALOID, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 18. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 22. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 23. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 24. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALIZED CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 25. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 26. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 27. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 28. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 29. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 30. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 31. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 32. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 33. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 34. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 35. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 36. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 37. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 38. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 39. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 40. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 41. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 42. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 43. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 44. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 45. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 46. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 47. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 48. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 49. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 50. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 51. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 52. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 53. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 54. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 55. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 56. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 57. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 58. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 59. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 60. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 61. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 62. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 63. CHINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 64. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 65. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 66. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 67. INDIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 68. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 69. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 70. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 71. INDONESIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 72. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 73. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 74. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 75. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 76. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 77. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 78. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 79. MALAYSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 80. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 81. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 82. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 83. PHILIPPINES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 84. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 85. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 86. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 87. SINGAPORE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 88. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 89. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 90. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 91. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 92. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 93. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 94. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 95. TAIWAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 96. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 97. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 98. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 99. THAILAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 100. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 101. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 102. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 103. VIETNAM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 104. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 105. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 106. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 107. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 108. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 109. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 110. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 111. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 112. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 113. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 114. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 115. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 116. EGYPT GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 117. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 118. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 119. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 120. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 121. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 122. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 123. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 124. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 125. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 126. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 127. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 128. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 129. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 130. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 131. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 132. ISRAEL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 133. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 134. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 135. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 136. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 137. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 138. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 139. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 140. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 141. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 142. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 143. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 144. NIGERIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 145. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 146. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 147. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 148. NORWAY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 149. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 150. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 151. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 152. POLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 153. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 154. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 155. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 156. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 157. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 158. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 159. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 160. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 161. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 162. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 163. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 164. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 165. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 166. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 167. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 168. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 169. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 170. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 171. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 172. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 173. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 174. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 175. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 176. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 177. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 178. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 179. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 180. SWITZERLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 181. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 182. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 183. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 184. TURKEY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 185. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 186. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 187. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 188. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 189. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 190. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 191. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 192. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 193. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- TABLE 194. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 195. GYNECOLOGICAL CANCER DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-DD0700E81D11
[195 Pages Report] The Gynecological Cancer Drugs Market size was estimated at USD 9.36 billion in 2023 and expected to reach USD 10.35 billion in 2024, at a CAGR 11.95% to reach USD 20.65 billion by 2030.
Global Gynecological Cancer Drugs Market
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 9.36 billion |
| Estimated Year [2024] | USD 10.35 billion |
| Forecast Year [2030] | USD 20.65 billion |
| CAGR (%) | 11.95% |
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Gynecological Cancer Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gynecological Cancer Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Gynecological Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., Apotex Pharmaceutical Holdings Inc., AstraZeneca PLC, Bayer AG, Biocon Limited, Bristol-Myers Squibb Company, Clovis Oncology, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline PLC, ImmunoGen, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., TherapeuticsMD Inc., and VBL Therapeutics, Inc..
Market Segmentation & Coverage
This research report categorizes the Gynecological Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Indication
- Cervical Cancer
- Chemotherapy
- Ovarian & Fallopian Tube Cancer
- Uterine Cancer
- Vaginal Cancer
- Vulvar Cancer
- Drug Class
- Alkylating Agent
- Anthracyclines
- Antitumor Antibiotic
- Plant Alkaloid
- Distribution Channel
- E-commerce
- Hospital Pharmacies
- Retail Pharmacies
- End-users
- Clinics
- Hospitals
- Specialized Cancer Treatment Centers
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Gynecological Cancer Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gynecological Cancer Drugs Market?
3. What are the technology trends and regulatory frameworks in the Gynecological Cancer Drugs Market?
4. What is the market share of the leading vendors in the Gynecological Cancer Drugs Market?
5. Which modes and strategic moves are suitable for entering the Gynecological Cancer Drugs Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Gynecological Cancer Drugs Market, by Region
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of various gynecological cancers
- 5.1.1.2. Increasing aging female population and rising healthcare awareness
- 5.1.1.3. Government initiatives to develop both therapeutic and preventive drugs
- 5.1.2. Restraints
- 5.1.2.1. High cost and quality issues associated with formulation of gynecological cancer drugs
- 5.1.3. Opportunities
- 5.1.3.1. Development and introduction of novel ovarian cancer treatments
- 5.1.3.2. Increasing investments to modernized healthcare infrastructure and novel drugs
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulatory frameworks associated with approval of drugs
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
6. Gynecological Cancer Drugs Market, by Indication
- 6.1. Introduction
- 6.2. Cervical Cancer
- 6.3. Chemotherapy
- 6.4. Ovarian & Fallopian Tube Cancer
- 6.5. Uterine Cancer
- 6.6. Vaginal Cancer
- 6.7. Vulvar Cancer
7. Gynecological Cancer Drugs Market, by Drug Class
- 7.1. Introduction
- 7.2. Alkylating Agent
- 7.3. Anthracyclines
- 7.4. Antitumor Antibiotic
- 7.5. Plant Alkaloid
8. Gynecological Cancer Drugs Market, by Distribution Channel
- 8.1. Introduction
- 8.2. E-commerce
- 8.3. Hospital Pharmacies
- 8.4. Retail Pharmacies
9. Gynecological Cancer Drugs Market, by End-users
- 9.1. Introduction
- 9.2. Clinics
- 9.3. Hospitals
- 9.4. Specialized Cancer Treatment Centers
10. Americas Gynecological Cancer Drugs Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
11. Asia-Pacific Gynecological Cancer Drugs Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
12. Europe, Middle East & Africa Gynecological Cancer Drugs Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. AbbVie Inc.
- 14.1.3. Alnylam Pharmaceuticals, Inc.
- 14.1.4. Amgen Inc.
- 14.1.5. Apotex Pharmaceutical Holdings Inc.
- 14.1.6. AstraZeneca PLC
- 14.1.7. Bayer AG
- 14.1.8. Biocon Limited
- 14.1.9. Bristol-Myers Squibb Company
- 14.1.10. Clovis Oncology
- 14.1.11. Dr. Reddy's Laboratories Ltd.
- 14.1.12. Eli Lilly and Company
- 14.1.13. F. Hoffmann-La Roche Ltd.
- 14.1.14. Genentech Inc.
- 14.1.15. GlaxoSmithKline PLC
- 14.1.16. ImmunoGen, Inc.
- 14.1.17. Johnson & Johnson Services, Inc.
- 14.1.18. Merck & Co., Inc.
- 14.1.19. Novartis AG
- 14.1.20. Pfizer Inc.
- 14.1.21. Sanofi SA
- 14.1.22. Takeda Pharmaceutical Co., Ltd.
- 14.1.23. Teva Pharmaceutical Industries Ltd.
- 14.1.24. TherapeuticsMD Inc.
- 14.1.25. VBL Therapeutics, Inc.
- 14.2. Key Product Portfolio
15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
